NAD+ injections and IV drips: what NAD+ is for and what the evidence shows
Published November 12, 2026. Sources last read November 12, 2026. Information only, not medical advice. Ask a licensed clinician before you start or stop any treatment.
The short answer
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, central to how cells make energy. IV NAD+ is used commercially to raise NAD+ levels. [1][2]
Most human trials of NAD+ boosters used oral NR or NMN, not NAD+ itself. A 2026 review found no randomized placebo-controlled trials of IV NAD+ and called the evidence preliminary. [6][2]
Reported side effects of IV NAD+ include nausea, cramping, flushing and chest discomfort. [2]
NAD is on the FDA's Category 1 list, bulk substances under evaluation for 503A compounding. [7]
Cheapest NAD+ this week
CoreAge Rxfrom $93 a month, no membership fee. No long-term contractNAD+ injectionChecked November 21, 2026 on CoreAge Rx's own pageCheck price at CoreAge Rx →
CoreAge Rxfrom $93 a month, no membership fee. No long-term contractNAD+ nasal sprayChecked November 21, 2026 on CoreAge Rx's own pageCheck price at CoreAge Rx →
BiltRxfrom $97 a month, with consultation and shipping billed separatelyNAD+ injectionChecked November 21, 2026 on BiltRx's own pageSee prices
Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money
Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money
Programs pay us when you sign up through our links. Affiliate disclosure
Every NAD+ price we track, cheapest first: the NAD+ price chart.
What NAD+ is and what it is for
NAD+ is a coenzyme found in all cells. A 2026 review says it takes part in more than 500 enzyme reactions. [1][2]
With its partner NADH, NAD+ is central to making cellular energy (ATP) in the mitochondria. [1]
The body can make NAD+ from forms of vitamin B3 such as nicotinamide, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). [2][1]
IV NAD+ is used commercially in wellness settings to raise NAD+ levels. A 2026 review judged the evidence not enough to support routine clinical or wellness use. [2]
Does NAD+ fall with age?
A 2023 review says age and many diseases are linked with lower NAD+ levels. [6]
A 2021 review of studies in several species found the evidence that NAD+ falls with age is very limited, and weakest in humans. A 2026 review cites a large study in which whole-blood NAD+ was not tied to age once disease burden was taken into account. [4][2]
What the evidence shows
Most human trials have used oral NR or NMN. A 2023 review of those trials says it is unclear whether raising NAD+ improves how the body works, and that small studies limit what the results can show. [6]
A 2018 randomized, double-blind, placebo-controlled crossover trial tested oral NR in healthy middle-aged and older adults. [5]
For IV NAD+, a 2026 review says the human evidence is sparse: mostly small uncontrolled studies, observational reports and case reports. It found no randomized placebo-controlled trials and no direct evidence that IV NAD+ beats oral supplements, and it judged the evidence not enough to support routine use. [2]
A 2019 pilot gave 8 healthy men aged 30 to 55 an IV drip of NAD+ and 3 a saline drip. Plasma NAD+ did not change until after 2 hours. Its authors said no human data on directly infused NAD+ existed before their study. [1]
Forms
An IV drip puts NAD+ straight into the blood. A 2026 review says many commercial IV protocols have not been formally validated and vary in amount and drip time, and that clinics often prefer slow drips of 2 to 4 hours. [2]
The human studies in this guide used IV drips or oral precursors, not the under-the-skin injections or nasal sprays that telehealth programs sell. [2][6]
Side effects in the studies
A 2026 review lists nausea, cramping, flushing and chest discomfort as reported side effects of IV NAD+, and says discomfort is more likely when the drip runs fast. [2]
A study of clinic records compared IV NAD+ with IV NR on four days in a row. People given NAD+ reported moderate to severe stomach symptoms, a faster heart rate and chest pressure during the drip, and all symptoms went away when it ended. NAD+ drips took 97 minutes on average against 37 for NR. Liver, kidney, thyroid and inflammation markers did not change significantly. [3]
The 2019 pilot reported no adverse events during its 6-hour drip. [1]
FDA status and compounding
The FDA's 503A list names NAD in Category 1, bulk drug substances under evaluation. A different form, beta-NAD disodium salt trihydrate, is in Category 3, nominated without enough support. [7]
The FDA says it does not intend to act against a pharmacy compounding with a Category 1 substance if the conditions in its guidance are met. [8]
The FDA says it does not check compounded drugs for safety, effectiveness or quality before they are sold, and that they are meant for patients whose needs an approved drug cannot meet. [9]
Sources
- Pilot study of the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+, Frontiers in Aging Neuroscience, via PMC, 2019-09-12. Read November 12, 2026. Our saved copy.
- Narrative review of intravenous NAD+ and NAD+ precursors, Frontiers in Aging, via PMC, 2026-09-10. Read November 12, 2026. Our saved copy.
- IV NAD+ versus IV nicotinamide riboside: a retrospective tolerability pilot study, Frontiers in Aging, via PMC, 2026-02-02. Read November 12, 2026. Our saved copy.
- Age-dependent decline of NAD+: universal truth or confounded consensus?, Nutrients, via PMC, 2021-12-27. Read November 12, 2026. Our saved copy.
- Chronic nicotinamide riboside supplementation in healthy middle-aged and older adults (randomized crossover trial), Nature Communications, via PMC, 2018-03-29. Read November 12, 2026. Our saved copy.
- Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions, Journals of Gerontology Series A, via PMC, 2023-04-17. Read November 12, 2026. Our saved copy.
- Bulk drug substances nominated for use in compounding under section 503A (categories 1, 2 and 3), FDA, 2026-05-14. Read November 12, 2026. Our saved copy.
- Bulk drug substances used in compounding under section 503A of the FD&C Act, FDA. Read November 12, 2026. Our saved copy.
- Compounding and the FDA: questions and answers, FDA. Read November 12, 2026. Our saved copy.
How we check sources: editorial policy. Rules for compounded peptides: FDA status of every peptide we track.